Literature DB >> 22203542

Missing the mark on prostate-specific antigen screening.

David C Miller1, Brent K Hollenbeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203542     DOI： 10.1001/jama.2011.1879

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  8 in total

Review 1.  Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Authors:  Daniel P Petrylak; E David Crawford
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

2.  CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.

Authors:  Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

3.  A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.

Authors:  Simon P Kim; R Jeffrey Karnes; Paul L Nguyen; Jeanette Y Ziegenfuss; R Houston Thompson; Leona C Han; Nilay D Shah; Marc C Smaldone; Cary P Gross; Igor Frank; Christopher J Weight; Timothy J Beebe; Jon C Tilburt
Journal:  BJU Int       Date:  2014-01-17       Impact factor: 5.588

4.  Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity?

Authors:  Yuanyuan Liang; Fei Du; Ian M Thompson; Barbara J Turner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-07-20       Impact factor: 4.254

5.  National evidence on the use of shared decision making in prostate-specific antigen screening.

Authors:  Paul K J Han; Sarah Kobrin; Nancy Breen; Djenaba A Joseph; Jun Li; Dominick L Frosch; Carrie N Klabunde
Journal:  Ann Fam Med       Date:  2013 Jul-Aug       Impact factor: 5.166

6.  Five-year downstream outcomes following prostate-specific antigen screening in older men.

Authors:  Louise C Walter; Kathy Z Fung; Katharine A Kirby; Ying Shi; Roxanne Espaldon; Sarah O'Brien; Stephen J Freedland; Adam A Powell; Richard M Hoffman
Journal:  JAMA Intern Med       Date:  2013-05-27       Impact factor: 21.873

7.  The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.

Authors:  Bret T Howrey; Yong-Fang Kuo; Yu-Li Lin; James S Goodwin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-05-04       Impact factor: 6.053

8.  Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.

Authors:  Melissa R Partin; Sarah E Lillie; Katie M White; Timothy J Wilt; Kristin L Chrouser; Brent C Taylor; Diana J Burgess
Journal:  Health Expect       Date:  2016-11-02       Impact factor: 3.377
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.